Skip to main content
Journal cover image

Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.

Publication ,  Journal Article
Gronwald, J; Robidoux, A; Kim-Sing, C; Tung, N; Lynch, HT; Foulkes, WD; Manoukian, S; Ainsworth, P; Neuhausen, SL; Demsky, R; Eisen, A; Eng, C ...
Published in: Breast cancer research and treatment
July 2014

Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of approximately 80 %. Tamoxifen treatment of the first cancer has been associated with a reduction in the risk of a subsequent contralateral cancer. We studied 1,504 women with a known BRCA1 or BRCA2 mutation, 411 women with bilateral breast cancer (cases) and 1,093 women with unilateral breast cancer (controls) in a matched case-control study. Control women were of similar age and had a similar age of diagnosis of first breast cancer as the cases. For each woman who used tamoxifen, the starting and stopping dates were abstracted and the duration of tamoxifen use was calculated. Three hundred and thirty-one women had used tamoxifen (22 %); of these 84 (25 %) had completed four or more years of tamoxifen, the remainder stopped prematurely or were current users. For women with up to 1 year of tamoxifen use, the odds ratio for contralateral breast cancer was 0.37 (95 % CI 0.20-0.69; p = 0.001) compared to women with no tamoxifen use. Among women with 1-4 years of tamoxifen use the odds ratio was 0.53 (95 % CI 0.32-0.87; p = 0.01). Among women with four or more years of tamoxifen use the odds ratio was 0.83 (95 % CI 0.44-1.55; p = 0.55). Short-term use of tamoxifen for chemoprevention in BRCA1 and BRCA2 mutation carriers may be as effective as a conventional 5-year course of treatment.

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Breast cancer research and treatment

DOI

EISSN

1573-7217

ISSN

0167-6806

Publication Date

July 2014

Volume

146

Issue

2

Start / End Page

421 / 427

Related Subject Headings

  • Time Factors
  • Tamoxifen
  • Risk Factors
  • Oncology & Carcinogenesis
  • Odds Ratio
  • Neoplasms, Second Primary
  • Mutation
  • Middle Aged
  • Humans
  • Heterozygote
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gronwald, J., Robidoux, A., Kim-Sing, C., Tung, N., Lynch, H. T., Foulkes, W. D., … Hereditary Breast Cancer Clinical Study Group, . (2014). Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 146(2), 421–427. https://doi.org/10.1007/s10549-014-3026-3
Gronwald, Jacek, Andre Robidoux, Charmaine Kim-Sing, Nadine Tung, Henry T. Lynch, William D. Foulkes, Siranoush Manoukian, et al. “Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.Breast Cancer Research and Treatment 146, no. 2 (July 2014): 421–27. https://doi.org/10.1007/s10549-014-3026-3.
Gronwald J, Robidoux A, Kim-Sing C, Tung N, Lynch HT, Foulkes WD, et al. Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast cancer research and treatment. 2014 Jul;146(2):421–7.
Gronwald, Jacek, et al. “Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.Breast Cancer Research and Treatment, vol. 146, no. 2, July 2014, pp. 421–27. Epmc, doi:10.1007/s10549-014-3026-3.
Gronwald J, Robidoux A, Kim-Sing C, Tung N, Lynch HT, Foulkes WD, Manoukian S, Ainsworth P, Neuhausen SL, Demsky R, Eisen A, Singer CF, Saal H, Senter L, Eng C, Weitzel J, Moller P, Gilchrist DM, Olopade O, Ginsburg O, Sun P, Huzarski T, Lubinski J, Narod SA, Hereditary Breast Cancer Clinical Study Group. Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast cancer research and treatment. 2014 Jul;146(2):421–427.
Journal cover image

Published In

Breast cancer research and treatment

DOI

EISSN

1573-7217

ISSN

0167-6806

Publication Date

July 2014

Volume

146

Issue

2

Start / End Page

421 / 427

Related Subject Headings

  • Time Factors
  • Tamoxifen
  • Risk Factors
  • Oncology & Carcinogenesis
  • Odds Ratio
  • Neoplasms, Second Primary
  • Mutation
  • Middle Aged
  • Humans
  • Heterozygote